Standout data in hard-to-treat cancer
Four in five injected tumours shrank or vanished; most not returning at six months.
QBiotics Group: Nature's Shot at Cancer
An unlisted Australian biotech (pre-IPO) turning rainforest-derived small molecules into new medicines through its platform technology. With its lead injectable anticancer drug showing promise across a range of solid tumours and receiving standout early trial results, its sights are set on a pharma partnership and future IPO.
Updated: Aug 19, 2026
Healthcare
microrow
Bull & Bear Case
An overview of the main reasons to invest and the key risks involved.
Bull Case
Lead drug delivered directly into the tumour, not through the bloodstream
Destroys the tumour at the source with minimal side effects while also triggering a systemic immunological response. Large market potential.
Not just a single drug but a platform of interrelated programmes
Family of unique small molecules underpins multiple programmes, with breadth and continuity that a single-asset company lacks.
A focused strategy aimed at an IPO
With commercial manufacturing capability in place and proof-of-concept data demonstrated, ambitions set on a commercial partner and float.
Bear Case
Multiple small trials point to broad potential, but a long road ahead
Early-stage trials with no Phase III yet mean bigger studies could disappoint.
A stretched balance sheet
Cash reserves have reduced, and more funding will be needed to continue.
Despite being a broad platform technology, a lot rides on the lead programme
Value rests on the anticancer programme and on securing a pharma partner.
Executive Summary
About QBiotics
Most anticancer drugs travel through the whole body to reach a tumour, which caps the dose a patient can tolerate and often blunts the drug's force by the time it arrives. For the many solid tumours that shrug off standard immunotherapy, useful options are still thin. QBiotics takes a different route. Its lead anticancer drug, tigilanol tiglate, is injected straight into a tumour, where it destroys the mass locally and rouses the immune system to finish the job. The small molecule comes from the blushwood tree of the Queensland rainforest, and a veterinary version, STELFONTA, is already registered and sold to treat cancer in dogs across the US, Europe, the UK and Australia.
Investor interest has grown because the early human results are hard to ignore. In its first soft tissue sarcoma trial, four in five injected tumours shrank or were destroyed outright, and none of the fully destroyed tumours had returned six months later. For a cancer that surgery, chemotherapy and radiotherapy often fail to control, that is a striking signal. The company's business model is to develop programmes to Phase II proof of concept, and its stated priority is to sign a global pharmaceutical partner for the anticancer programme with the next focus on developing its Phase I wound healing programme through to Phase II in preparation for partnering. This is still a loss-making, unlisted, early-stage business that is burning cash and will need to raise more to reach a deal. Against that, it can point to strong trial results, a lean, capital-light model that makes its funding go further, and FDA orphan-drug status in the US that brings tax breaks and a period of market exclusivity if the drug reaches approval.
Investor interest has grown because the early human results are hard to ignore. In its first soft tissue sarcoma trial, four in five injected tumours shrank or were destroyed outright, and none of the fully destroyed tumours had returned six months later. For a cancer that surgery, chemotherapy and radiotherapy often fail to control, that is a striking signal. The company's business model is to develop programmes to Phase II proof of concept, and its stated priority is to sign a global pharmaceutical partner for the anticancer programme with the next focus on developing its Phase I wound healing programme through to Phase II in preparation for partnering. This is still a loss-making, unlisted, early-stage business that is burning cash and will need to raise more to reach a deal. Against that, it can point to strong trial results, a lean, capital-light model that makes its funding go further, and FDA orphan-drug status in the US that brings tax breaks and a period of market exclusivity if the drug reaches approval.
Investment Thesis
Overview of buy and sell case of the business.
Why Invest?
Key pieces of information about the business that you need to know about.
Standout data in hard-to-treat cancer
Around 90% of cancers are solid tumours, the category this drug targets, though so far it has only been tested in a handful of them. The early results, however, are hard to ignore. In a Phase IIa soft tissue sarcoma study at Memorial Sloan Kettering New York, four of every five injected tumours were destroyed outright, or shrank significantly and none of the fully destroyed tumours had returned six months later.
A second trial, in head and neck cancer with the Royal Marsden London as the lead site, has now reported a near-identical result: close to four in five injected tumours responded, with no recurrences during the study. That is a rare signal for cancers that surgery, chemotherapy, radiotherapy and immunological therapy often fail to control.
The US FDA regulator has granted the drug orphan-drug status for soft tissue sarcoma, a designation for rare-disease treatments that brings tax breaks, fee waivers, closer work with the regulator and up to seven years of market exclusivity once approved. Due to impressive results from Compassionate Use at the Gustave Roussy Cancer Centre in Paris, Unicancer, the French Federation of Cancer Centres, is supporting the majority of costs of a Phase II trial in breast cancer which is soon to commence.
Lead drug delivered directly into the tumour, not through the bloodstream
Conventional cancer drugs travel through the whole bloodstream to reach a tumour, which is why chemotherapy causes side effects across the body and why doses have to be capped. Tigilanol tiglate flips that model. It is injected straight into the tumour, usually in a single dose, where it destroys the blood supply, kills the cancer cells within hours, and stimulates the site to heal with minimal to no scarring. And it can also prompt the immune system to attack cancer elsewhere.
Because it acts locally and clears the bloodstream fast, side effects are mild and transient and stay confined to the treated area. For patients, that points to a faster, more targeted treatment that could spare much of the toll of whole-body therapy.
Not just a single drug but a platform of interrelated programmes
Rather than resting on a single drug, the company's value lies in a platform of interrelated programmes built on a family of unique small molecules, both isolated and semi-synthetic in origin. This shared molecular platform underpins multiple programmes in cancer, wound healing and antibiotics giving the pipeline a breadth and continuity that a single-asset company would lack.
A focused strategy aimed at an IPO
Management has stripped the plan back to one path: license the anticancer drug to a global pharmaceutical partner, results of which will underpin a stock market flotation. The venue and timing will follow investor demand, but the direction is set. It brings an unusually complete package to partner talks.
A version of the drug is already registered and sells in major markets as an approved veterinary cancer drug, which validates the science and supplies the manufacturing and safety data a partner needs, while the drug's comparatively easy manufacturing, long shelf life and simple storage make it easier to commercialise than rival injected therapies. A lean, capital-light model helps to utilise each dollar to reach the goal.
Catalysts
The key events that could drive investment opportunities and shift markets.
- Breast cancer trial: The Phase II study with Unicancer, the next tumour-type test for the drug, is due to start.
- Securing a partner: Concrete progress in the partnering talks, from a formal collaboration to signed licensing terms, would show the core strategy is working.
- More soft tissue sarcoma data: Further results from the expanded trial would reinforce the momentum built by the strong early data.
- Funding secured: A prospectus is open to raise up to A$40m (minimum A$5m); completing it would ease the cash pressure and buy time to reach a deal.
- A stock market listing: A float, which management is working toward once a partner deal is in hand.
- Success in more cancer types: Positive data in new tumours and in combination with other treatments such as the immune checkpoint inhibitors, plus progress from the earlier-stage wound-healing (EBC-1013) and antibiotic programmes.
Key Risks
Key pieces of information about the business risks that you need to know about.
Multiple small trials point to broad potential, but a long road ahead
The headline results come from small, mostly single-arm studies of a handful of patients, with no pivotal Phase III yet. Early efficacy often fades under the scrutiny of larger controlled trials. A second positive readout, in head and neck cancer, still needs confirming in bigger studies, and a breast cancer trial is the next test. A melanoma trial combining the drug with a checkpoint inhibitor was discontinued due to difficulty in patient recruitment during COVID, a reminder that not every programme survives contact with the clinic.
A stretched balance sheet
QBiotics loses money and funds itself by raising it. Cash fell from about A$25.8m in mid-2025 to roughly A$12.5m by 30 June 2026, and the auditor has noted that the company will need further funding to continue its research, a common position for a business at this stage but one that keeps the pressure on. The company has now moved to address that, lodging a prospectus in August 2026 to raise up to A$40m from new and existing shareholders, with a minimum of A$5m.
Despite being a broad platform technology, a lot rides on the lead programme
Much of the investment case rests on one small molecule, the anticancer intratumoural drug tigilanol tiglate, and on the plan to license it to a larger pharmaceutical company and then list. The company's only product revenue today comes from STELFONTA, the veterinary version of the drug used to treat tumours in dogs. It is small and shrinking, down from A$1.28m to A$0.84m last year, and it depends on a single distributor which the company is currently replacing.
There are Phase I wound healing and early preclinical antibiotics programmes emerging from the same discovery platform, but these remain years from market. If the data stalls for the anticancer treatment, or a partner fails to materialise on good terms, the wound healing programme would first need to be brought to Phase II proof of concept before it could support any further commercialisation.
Follow the Experts
Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence.
Investor Materials
Access the most recent investor updates published by the company.
Key Documents
Shareholder Update June 2026
PDFAnnual Report 2025
PDFTeam
Meet the experienced professionals leading our organization
Simon Pollard
Ebru Davidson
Dr Victoria Gordon
Dr Paul Reddell
What the Pros are asking
Here are the questions that institutional investors are asking before making an investment decision.
How much weight can the early efficacy really carry?
An 80% response rate is a strong signal, and it holds up in ways that matter: no recurrences at six months, a consistent effect across different tumours, and an orphan-drug designation from the FDA. The fair caution is scale. The soft tissue sarcoma figure comes from around ten evaluable patients, and it measures response in the injected tumour rather than control of the whole disease. A second trial, in head and neck cancer, has now reported a near-identical 78% response rate from 14 patients, reinforcing that the effect holds across tumour types. The next test is breast cancer, where a trial is still to come. On the evidence so far, the signal is unusually good for this stage.
How large is the opportunity for an injected therapy?
A drug given by needle reaches tumours a clinician can inject, so accessible and earlier-stage cancers are the natural starting point. Notably, imaging and injection technology advances now enable intratumoural treatment of internally located tumours anywhere in the body, a capability the company has progressed into preclinical assessment. With solid tumours making up around 90% of cancers, even a slice is substantial. The bigger prize is the immune response the injection sets off, which appears to act on cancer beyond the treated site and opens the door to combining with immunotherapies.
What are the chances of landing a pharma partner?
Partnering is the pivot of the whole strategy, and QBiotics brings an unusually complete package to the table for its stage: an approved animal version of the drug, established manufacturing, toxicology, and broad clinical signals. Set against that, biotech deals take time, and terms depend on how mature and competitive the data looks when talks conclude. No agreement has been struck yet. The encouraging read is that the company has more of the groundwork done than most peers seeking a deal.
Is the company funded to reach a deal?
Cash at bank as at 31 December 2025 was A$13.5m, against a history of spending several million a quarter, so funding is the tightest variable. In its favour, the cost base has been cut, a sizeable government R&D rebate comes in each year, and management has now lodged a prospectus to raise up to A$40m, with a minimum of A$5m, to carry it to a partnering deal.
What sets this apart in a competitive field?
Injecting therapy into tumours is an active, fast-growing area, led by oncolytic viruses such as the approved T-VEC. Tigilanol tiglate's distinction is that it is a small molecule rather than a virus: quicker and cheaper to make, with a long shelf life and simple refrigeration instead of a deep-freeze cold chain, plus real-world veterinary use behind it. Larger, better-funded rivals are pursuing the same immune effect, so leadership will be decided by data and by the economics of manufacturing and delivery, where the drug starts from a genuine advantage.